Vor Biopharma Inc.
VORHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeVor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The $811.2M market capitalization puts VOR squarely in small-cap range for its industry. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy.
Market Cap
$811.2M
Beta
—
P/E (TTM)
—
P/E (Fwd)
-4.00
EPS (TTM)
$-70.40
EPS (Fwd)
$-3.74
ROE
—
ROA
-69.8%
Cash
$491.5M
Total Debt
$2.9M
Free CF
-$195.8M
52W Change
219.9%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $491.5M in cash comfortably exceeding the $2.9M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$195.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time.
With cash comfortably exceeding debt, VOR has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing VOR's risk profile alongside its fundamentals and technical indicators provides a more complete picture.